![]() ![]() Significant Metabolites Associated With GCIPLTĮTable 6. Baseline Characteristics of the Study Population from the GDES CohortĮTable 5. Baseline Characteristics of the Study Population from the UKB CohortĮTable 4. Metabolic Markers Used in Models Discriminating Common Diseases and MortalityĮTable 3. List Summarizing All Metabolic Markers Quantifying Using 1H-NMR ProfilingĮTable 2. ![]() Net Benefit Curves of Clinical Utility for Common Diseases and MortalityĮTable 1. Calibration Plots Illustrating Predicted and Observed Probabilities for Common Diseases and MortalityĮFigure 9. Receiver Operating Characteristic Curves of Clinical Indicators-based Models, GCIPLT Metabolic State Models, and Combined Models for Predicting Common Diseases and MortalityĮFigure 8. Predictive Power of GCIPLT Metabolic Profiles and Clinical Indicators for Common Diseases and MortalityĮFigure 7. Cumulative Event Rates Over the Observation Time for Common Diseases and MortalityĮFigure 6. Associations of GCIPLT Metabolic Profiles and Risk of Morbidity of Common Diseases and MortalityĮFigure 5. Heatmaps Demonstrating the Overall Correlations of GCIPLT and MetabolitesĮFigure 4. Analytic Framework of the StudyĮFigure 3. It may be more useful for detecting progression in the advanced stages of glaucoma than RNFL GPA.Ĭopyright © 2017 American Academy of Ophthalmology. Ganglion cell-inner plexiform layer GPA provides a new approach for evaluating glaucoma progression. However, the rate of change in the average RNFL thickness did not differ significantly in moderate to advanced glaucoma (P = 0.765 -0.26☐.55 μm/year for progressors and -0.33☐.92 μm/year for nonprogressors), and VF survival estimates did not differ significantly between eyes with and without progressive RNFL thinning in moderate to advanced glaucoma (P = 0.781). Eyes with progressive GCIPL thinning had lower VF survival estimates than eyes without, regardless of glaucoma severity. The rate of change in the average GCIPL thickness was significantly higher in progressors (-1.05☐.98 μm/year for mild glaucoma and -0.66☐.30 μm/year for moderate to advanced glaucoma) than in nonprogressors (-0.47☐.54 μm/year for mild glaucoma and -0.31☐.50 μm/year for moderate to advanced glaucoma), regardless of glaucoma severity (P < 0.05). Seventy-six eyes (38.8%) and 43 eyes (21.9%) demonstrated progressive GCIPL and RNFL thinning, respectively, and 48 eyes (24.5%) were classified as progressors by reference standard. Progressive GCIPL and RNFL thinning assessed by OCT GPA. Visual field survival estimates in eyes with and without progressive GCIPL and RNFL thinning were evaluated by Kaplan-Meier survival analysis and compared with the log-rank test. Ganglion cell-inner plexiform layer and RNFL thinning rates were compared between progressors and nonprogressors. Glaucomatous eyes were classified into mild (117 eyes) or moderate to advanced (79 eyes) groups based on VF defects. The reference standard of glaucoma progression was determined by visual field (VF) progression. Macular GCIPL and peripapillary RNFL thicknesses were measured by Cirrus HD-OCT (Zeiss, Dublin, CA), and progressive GCIPL and RNFL thinning were assessed by GPA. To examine the performance of Guided Progression Analysis (GPA Carl Zeiss Meditec, Dublin, CA) in spectral-domain optical coherence tomography (OCT) in detecting progressive thinning of ganglion cell-inner plexiform layer (GCIPL) and retinal nerve fiber layer (RNFL) in glaucoma.Ī total of 196 eyes of 123 primary open-angle glaucoma patients (mean follow-up, 5.0 years). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |